Business Wire

BITFURY-GROUP

4.11.2021 13:02:08 CET | Business Wire | Press release

Share
Bitfury Appoints Former United States Acting Comptroller of the Currency Brian P. Brooks Chief Executive Officer

Bitfury Group (“Bitfury” or the “Company”), the Bitcoin mining and crypto tech pioneer, today announced that Brian P. Brooks, former United States Acting Comptroller of the Currency, has joined the Company as Chief Executive Officer, effective October 29, 2021. Mr. Brooks will lead the 10-year-old crypto unicorn as it launches a new funding round, increases the growth of its mining business with a revolutionary new microchip design and new global data center locations, and scales a portfolio of innovative businesses that grew out of the Company’s heritage as an early Bitcoin leader. Valery Vavilov, Founder of Bitfury, will become Chairman of the Board of Directors and Chief Vision Officer, where he will continue his focus on developing over-the-horizon hardware and software innovations for Bitfury as it builds the infrastructure for a tokenized global economy.

Mr. Vavilov said, “Since our founding, Bitfury has pioneered innovative blockchain hardware and software infrastructure, and today represents a comprehensive platform addressing and enhancing the full digital asset value chain. With an eye toward the next phase in our evolution, we are thrilled to welcome Brian to the Company. Brian is a respected executive and thought leader with deep regulatory, digital asset and capital markets expertise who shares Bitfury’s vision for a decentralized peer-to peer economy. Together, we will continue to execute Bitfury’s growth strategy and help businesses, governments, organizations, and individuals leverage the blockchain to solve the most pressing challenges of today and tomorrow.”

Since its inception in 2011, Bitfury has developed into a full-service blockchain technology company and one of the world’s leading providers of large-scale digital asset infrastructure solutions. Bitfury’s platform of emerging technologies businesses includes its self-mining operations, with seven ultra-low-cost energy sites globally alongside its new United-States based Cipher Mining subsidiary; hardware products for high-performance computing needs, including seven generations of its own specialized micro-chips and next generation immersion cooling systems; and software and enterprise blockchain solutions spanning security, payments, and applications for the creator economy, among others.

Mr. Brooks said, “Bitfury is an established leader in the digital asset industry, renowned for its sustained research and development efforts and best-in-class proprietary technologies. As the adoption of – and use cases for – Bitcoin, other cryptoassets, and their underlying blockchains continues to accelerate worldwide, the Company’s diversified portfolio has immense opportunity and is well positioned for long-term success. I look forward to working alongside Valery and Bitfury’s highly experienced leadership team to grow the Company’s core businesses and scale its portfolio of new innovations.”

Brian P. Brooks Biography

Most recently, Mr. Brooks served as Chief Executive Officer of digital asset exchange and marketplace Binance.US. Previously, from May 2020 to January 2021, Mr. Brooks served as the Acting Comptroller of the Currency, where he was the administrator of the federal banking system and the chief executive of the 3,500-employee federal agency responsible for chartering and supervising banks comprising 70 percent of all banking activity in the United States. He also served as a member of the board of directors of the Federal Deposit Insurance Corporation and a voting member of the Financial Stability Oversight Council. Often referred to in the media as “the first fintech Comptroller” and “CryptoComptroller” for his work advancing financial innovation, Mr. Brooks led the government’s efforts to provide regulatory clarity for stablecoins, digital asset custody, and the development of blockchain payment networks, and granted the first federal bank charter to a cryptocurrency company. He also launched Project REACh, a national partnership of civil rights organizations, tech companies, and banks to promote financial inclusion through greater access to credit and capital.

From 2018 to 2020, Mr. Brooks served as Chief Legal Officer of Coinbase Global, Inc., where he led legal, compliance, internal audit, government relations, and global investigations groups at the digital asset platform. From 2014 to 2018, he served as Executive Vice President, General Counsel, and Corporate Secretary of Fannie Mae, a $3.2 trillion asset public company that is the world’s largest investor in single-family and multifamily mortgage assets, and from 2011 to 2014, as Vice Chairman of OneWest Bank, N.A. Before joining OneWest Bank, N.A., he served as managing partner of O’Melveny & Myers LLP’s Washington, D.C. office.

Mr. Brooks also serves as an adviser or board member for a number of financial and fintech companies. Mr. Brooks received his BA from Harvard University and his JD from the University of Chicago.

About Bitfury Group

Bitfury Group is the world's leading technology company unlocking the full value chain of Bitcoin and other digital assets. Bitfury™ has built on its heritage as one of the earliest Bitcoin miners and developers of mining equipment to create solutions for the future – solutions such as the Crystal™ Blockchain advanced analytics platform, which helps law enforcement and private sector clients make cryptoassets safer and more compliant; the Liquidstack immersion cooling business, which dramatically reduces data center energy usage and makes Bitcoin mining and high performance computing more environmentally sustainable; Axelera AI, which unlocks the potential of artificial intelligence with the world’s most advanced AI technologies; Surround, providing blockchain-based solutions for the creator economy including digital rights management, payments, and NFT support; and others. Our mission is to make the world more secure and trusted by innovating at every level of technology – hardware, security, and software – to put trust back into the equation. To learn more, visit www.bitfury.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye